{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:45:51Z","timestamp":1778507151109,"version":"3.51.4"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The FDA approved duvelisib, a PI3K\u03b4\/PI3K\u03b3 inhibitor, for patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma who have received at least two prior therapies. The agency also granted the drug an accelerated approval for patients with relapsed\/refractory follicular lymphoma following at least two other therapies.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2018-137","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T13:01:03Z","timestamp":1540299663000},"page":"OF4-OF4","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Duvelisib Approved for Leukemia, Lymphoma"],"prefix":"10.1158","volume":"8","member":"1086","published-online":{"date-parts":[[2018,12,3]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/12\/OF4\/191356\/Duvelisib-Approved-for-Leukemia-LymphomaDuvelisib","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/12\/OF4\/191356\/Duvelisib-Approved-for-Leukemia-LymphomaDuvelisib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:33:06Z","timestamp":1654579986000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/12\/OF4\/191356\/Duvelisib-Approved-for-Leukemia-LymphomaDuvelisib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,3]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2018-137","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}